China's Ministry of Commerce published a draft to tighten oversight of certain biotech exports, naming five biomedical technologies for control. Two of them are next generation platforms that target disease at the genetic level.
The proposal would impose stricter limits on transferring ownership of small interfering RNA molecules that can shut off genes linked to disease, and on cell and gene therapy platforms aimed at treating cancers and rare illnesses. It further extends to work and tools connected to disease-causing microorganisms.
China also signaled new curbs for areas such as artificial intelligence and solar energy technologies.
The draft makes clear that arrangements for licensing, partnerships, and contract research services that touch these technologies fall outside the limits. That keeps a critical channel open for foreign drugmakers that have helped power China's rise in pharma.
Global players such as AstraZeneca Plc and Pfizer Inc have been striking more cross border licenses for experimental drugs discovered by Chinese firms. According to government statistics, there were 81 licensing deals in the first half of 2026 with values reaching up to $110 billion - pointing to momentum that would overtake last year's record.
When policy shifts can affect sectors, stay informed with the free Market Briefs newsletter that summarizes key economic and market developments daily
Keeping licensing open should ease nerves across the industry. US and European companies say China's pipeline offers more innovative drugs with strong sales potential. For Chinese developers, these deals bring funding and global recognition, which supports Beijing's aim to be a leader in biomedical research.
Ryan Etzcorn of Ankura China Advisors, where he holds a senior director role, said, "The controls represent a new 'coming out' moment for China's confidence in how innovative and globally competitive its biomedicine sector has become." "Chinese biotech will be open for business, but closed to technology flight."
These collaborations have also become a flashpoint between Washington and Beijing. Some US lawmakers and investors want tighter limits, and the US Treasury Department is expected to issue rules this year that could place biotech licensing deals under the same outbound investment reviews used for semiconductors and artificial intelligence systems.
In plain English: China plans to limit ownership transfers of sensitive biotech while keeping license based collaboration intact. Deal flow can continue, but direct tech transfers face higher walls. Keep an eye on the final Chinese rules and any US outbound review moves - both will influence cross border pipelines, upfront payments, and royalty math for drug developers and their partners.
Because deals and regulations can change business outlooks, sign up for Market Briefs to get a clear market and economy update in five minutes
